Use of rescue medication · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
It is very uncertain whether intravenous ketorolac changes number of participants using rescue medication over 4 or 6 hours… compared with placebo (very low certainty).
1 finding from 1 review
Median (mean) time to use of rescue medication · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
1 finding from 1 review
Median (mean) time to use of rescue medication · health problem or population
1 finding from 1 review
Number of participants using rescue medication over 4 to 6 hours postinterventions · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Median (mean) time to use of rescue medication · health problem or population
1 finding from 1 review
Number of participants using rescue medication over 4 to 6 hours postinterventions · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence to pharmacotherapy: number of people achieving adherence to medication · COPD
Multi‐component intervention may leads to higher adherence to pharmacotherapy: number of people achieving adherence… compared with control (low certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to adhere to medication regimen compared with conventional dosing (low certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with sham (moderate certainty).
1 finding from 1 review
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes use of IOP‐lowering medications ‐ 24 months compared with sham (very low certainty).
1 finding from 1 review
RR 21.6 [1.32, 354.7]
Studies not reported
Very low
Use of IOP‐lowering medications · macular edema in diabetes
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher use of IOP‐lowering medications ‐ 9 to 24 months compared with macular laser (moderate certainty).
1 finding from 1 review
RR 3.92 [2.59, 5.96]
Studies not reported
Moderate
Use of IOP‐lowering medications · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low